Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Depreciation & Amortization (CF) (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Depreciation & Amortization (CF) data on record, last reported at $28000.0 in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) rose 33.33% year-over-year to $28000.0; the TTM value through Sep 2025 reached $99000.0, up 6.45%, while the annual FY2024 figure was $85000.0, 43.71% down from the prior year.
  • Depreciation & Amortization (CF) reached $28000.0 in Q3 2025 per CRVS's latest filing, down from $29000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $94000.0 in Q3 2022 and bottomed at $20000.0 in Q4 2024.
  • Average Depreciation & Amortization (CF) over 4 years is $45466.7, with a median of $29000.0 recorded in 2025.
  • Peak YoY movement for Depreciation & Amortization (CF): plummeted 70.21% in 2023, then soared 38.1% in 2025.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at $94000.0 in 2022, then tumbled by 70.21% to $28000.0 in 2023, then decreased by 28.57% to $20000.0 in 2024, then surged by 40.0% to $28000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $28000.0 in Q3 2025, $29000.0 in Q2 2025, and $22000.0 in Q1 2025.